Видео ютуба по тегу Nct02910583

CLL highlights from ASCO & EHA 2025: SEQUOIA, FLAIR, & CAPTIVATE trials
CLL highlights from ASCO & EHA 2025: SEQUOIA, FLAIR, & CAPTIVATE trials
ВБ арт. WW229262 ; ОЗОН арт. 3179585656 #обзор #уходзасобой
ВБ арт. WW229262 ; ОЗОН арт. 3179585656 #обзор #уходзасобой
Final analysis of the CAPTIVATE study and comparisons with the SEQUOIA trial
Final analysis of the CAPTIVATE study and comparisons with the SEQUOIA trial
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
Update on fixed-duration cohort of CAPTIVATE trial for CLL/SLL
Update on fixed-duration cohort of CAPTIVATE trial for CLL/SLL
CAPTIVATE: ibrutinib/venetoclax delivers high rates of uMRD in CLL
CAPTIVATE: ibrutinib/venetoclax delivers high rates of uMRD in CLL
Unanswered questions in frontline CLL treatment
Unanswered questions in frontline CLL treatment
CAPTIVATE study: outcomes in patients with uMRD following cessation of ibrutinib plus venetoclax
CAPTIVATE study: outcomes in patients with uMRD following cessation of ibrutinib plus venetoclax
CAPTIVATE trial: 5.5yr follow-up of the fixed-duration cohort
CAPTIVATE trial: 5.5yr follow-up of the fixed-duration cohort
Ibrutinib Plus Venetoclax in Patients With CLL/SLL
Ibrutinib Plus Venetoclax in Patients With CLL/SLL
2 year DFS data from the CAPTIVATE trial
2 year DFS data from the CAPTIVATE trial
CAPTIVATE: Ibrutinib and venetoclax in CLL
CAPTIVATE: Ibrutinib and venetoclax in CLL
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Optimizing the combination of ibrutinib plus venetoclax in CLL
Optimizing the combination of ibrutinib plus venetoclax in CLL
Positive results for CAPTIVATE: ibrutinib and venetoclax for CLL
Positive results for CAPTIVATE: ibrutinib and venetoclax for CLL
The prognostic value of MRD in CLL
The prognostic value of MRD in CLL
Pivotal findings at ASH 2020
Pivotal findings at ASH 2020
CAPTIVATE: 1-year DFS results from the MRD cohort in CLL
CAPTIVATE: 1-year DFS results from the MRD cohort in CLL
BTK inhibitor combinations for CLL
BTK inhibitor combinations for CLL
CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL
CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL